Trial Profile
An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Suratadenoturev (Primary)
- Indications Colon cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 19 Apr 2023 Final Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 10 Feb 2023 According to a Oncolys Biopharma, results of this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting in the U.S. in April 2023
- 24 Jan 2022 Status changed from active, no longer recruiting to completed.